NCT01033097 - Safety and Efficacy of DNK333 in Atopic Dermatitis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Pruritus in Patients With Atopic Dermatitis

Interventions

DRUG

DNK333 5 mg

5 mg oral

DRUG

Placebo to 5 mg

5 mg placebo oral

DRUG

DNK333 25 mg

25 mg oral

DRUG

Placebo to 25 mg

25 mg placebo oral

DRUG

DNK333 100 mg

100 mg oral

DRUG

Placebo to 100 mg

100 mg placebo oral

DRUG

Betamethasone 4 mg

4 mg oral

DRUG

DNK333 1mg

1 mg oral

DRUG

Placebo to 1mg

1 mg placebo oral

Trial Locations (5)

Novartis Investigative Site, Berlin

Novartis Investigative Site, Frankfurt

Novartis Investigator Site, Hanover

Novartis Investigative Site, Kiel

Novartis Investigative Site, Münster